Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8388948 | 0.98 | IDO1 (0.37) | IDO1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14917493 | 0.90 | — | — | |
| SCHEMBL23834982 | 0.80 | SMYD3 (0.36) | IDO1 | |
| SCHEMBL21789269 | 0.80 | SMYD3 (0.36) | IDO1 | |
| Hydrochloric Acid SCHEMBL21774820 | 0.79 | SMYD3 (0.36) | IDO1 | |
| Hydrochloric Acid SCHEMBL21774821 | 0.79 | SMYD3 (0.36) | IDO1 | |
| SCHEMBL12313120 | 0.74 | IDO1 (0.40) | IDO1 | |
| SCHEMBL1971343 | 0.74 | KMT2A (0.36) | IDO1ALDH1A1MEN1KMT2A | |
| SCHEMBL12436840 | 0.73 | KCNJ1 (0.33) | IDO1ALDH1A1 | |
| SCHEMBL30103385 | 0.71 | CYP2C19 (0.35) | ALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884118-B2 | such as 1-Cyclopentyl-5-iodotetrazole, suitable as microbicides for protecting plants and materials | LANXESS DEUTSCHLAND GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20090042960-A1 | 1-Cycloalkyl-5-Iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1904464-A1 | 1-CYCLOALKYL-5-IODOTETRAZOLES | Lanxess Deutschland GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007025586-A1 | 1-CYCLOALKYL-5-IODOTETRAZOLES | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042960-A1 | 1-Cycloalkyl-5-Iodotetrazoles | MSR1, CYP51A1, MCL1 | IDO1 24/4885ALDH1A1 314/4885SMN1; SMN2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.